IEX •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization44.02 mln
Float31.19 mln
Earnings Date11/23/2026
EPS
0.35
Marginal
P / E
4.00
Deeply undervalued
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
3.50
Transformational upside
Relative Strength
100
/ 100
Top performer
Debt / Equity
0.04
Debt-free
Business Description
Actinium Pharmaceuticals is a New York-based biotech company focused on developing radiation-based treatments for patients with cancer and other blood disorders who have not responded to standard therapies. Its pipeline includes several candidates targeting conditions such as acute myeloid leukemia, sickle cell disease, and prostate cancer, with approaches ranging from bone marrow transplant preparation to improving the effectiveness of CAR-T cell therapy. The company also works alongside the National Cancer Institute to advance its research and is exploring further treatments for solid tumors.